Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by ScienceFirston Jan 31, 2023 10:52pm
310 Views
Post# 35258571

The top 10 biopharma M&A deals of 2022

The top 10 biopharma M&A deals of 2022
For those that are not familiar with market valuations ...


Jan 30, 2023
 
 

Heading into 2022, top drugmakers had $1.7 trillion in dealmaking firepower, fueling expectations that the industry was due for a gangbuster year of M&A activity. Well, that didn’t quite pan out. 

Instead, the 10 largest biopharma M&A deals in 2022 totaled around $65 billion. While that was an increase from $53 billion in 2021, it was a notable downturn from prior years. 

 

In 2020, for instance, the 10 largest biopharma M&A deals totaled $97 billion in value. Before that, in 2019, the industry’s 10 largest deals came in at more than $200 billion.

While deal values—and volumes—may have disappointed some in 2022, PwC analysts see some reasons for a potential rebound. For 2023, the team said it expects an “active year” thanks to “ample” corporate cash, the need to fill pipeline gaps at Big Pharmas and “resetting” biotech valuations. Deals in the $5 billion to $15 billion range represent the “sweet spot,” according to the experts, but larger acquisitions could come later in the year. 
 
<< Previous
Bullboard Posts
Next >>